251 related articles for article (PubMed ID: 8881767)
1. Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis.
Lobo PI; Chang MY; Mellins E
Immunology; 1996 Aug; 88(4):625-9. PubMed ID: 8881767
[TBL] [Abstract][Full Text] [Related]
2. A novel role for MHC class II antigens: evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells.
Lobo PI; Patel HC
Immunology; 1994 Oct; 83(2):240-4. PubMed ID: 7835941
[TBL] [Abstract][Full Text] [Related]
3. Interaction of natural killer cells with MHC class II: reversal of HLA-DR1-mediated protection of K562 transfectant from natural killer cell-mediated cytolysis by brefeldin-A.
Jiang YZ; Couriel D; Mavroudis DA; Lewalle P; Malkovska V; Hensel NF; Dermime S; Molldrem J; Barrett AJ
Immunology; 1996 Mar; 87(3):481-6. PubMed ID: 8778037
[TBL] [Abstract][Full Text] [Related]
4. Bovine NK and LAK susceptibility is independent of class I expression on B lymphoblastoid variants.
Li W; Splitter GA
Vet Immunol Immunopathol; 1994 Jun; 41(3-4):189-200. PubMed ID: 7941303
[TBL] [Abstract][Full Text] [Related]
5. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
6. Culture medium induced morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells.
Perng YP; Lin CC; Perng IM; Shen YC; Chuang CK; Liao SK
Cancer Biother Radiopharm; 1997 Oct; 12(5):317-31. PubMed ID: 10851482
[TBL] [Abstract][Full Text] [Related]
7. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
8. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.
Jabrane-Ferrat N; Calvo F; Faille A; Lagabrielle JF; Boisson N; Quillet A; Fradelizi D
Br J Cancer; 1990 Apr; 61(4):558-62. PubMed ID: 2109997
[TBL] [Abstract][Full Text] [Related]
9. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
10. Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type.
Litwin V; Gumperz J; Parham P; Phillips JH; Lanier LL
J Exp Med; 1993 Oct; 178(4):1321-36. PubMed ID: 8376937
[TBL] [Abstract][Full Text] [Related]
11. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis.
Chang CS; Brossay L; Kronenberg M; Kane KP
J Exp Med; 1999 Feb; 189(3):483-91. PubMed ID: 9927510
[TBL] [Abstract][Full Text] [Related]
12. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis.
Chiang EY; Henson M; Stroynowski I
J Immunol; 2002 Mar; 168(5):2200-11. PubMed ID: 11859106
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
[TBL] [Abstract][Full Text] [Related]
14. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2).
Ciccone E; Pende D; Viale O; Than A; Di Donato C; Orengo AM; Biassoni R; Verdiani S; Amoroso A; Moretta A
J Exp Med; 1992 Oct; 176(4):963-71. PubMed ID: 1328466
[TBL] [Abstract][Full Text] [Related]
15. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
[TBL] [Abstract][Full Text] [Related]
16. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene.
Maio M; Altomonte M; Tatake R; Zeff RA; Ferrone S
J Clin Invest; 1991 Jul; 88(1):282-9. PubMed ID: 1905328
[TBL] [Abstract][Full Text] [Related]
17. General role of HLA class I molecules in the protection of target cells from lysis by natural killer cells: evidence that the free heavy chains of class I molecules are not sufficient to mediate the protective effect.
Ciccone E; Pende D; Nanni L; Di Donato C; Viale O; Beretta A; Vitale M; Sivori S; Moretta A; Moretta L
Int Immunol; 1995 Mar; 7(3):393-400. PubMed ID: 7794819
[TBL] [Abstract][Full Text] [Related]
18. Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.
Falk CS; Steinle A; Schendel DJ
J Exp Med; 1995 Oct; 182(4):1005-18. PubMed ID: 7561674
[TBL] [Abstract][Full Text] [Related]
19. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
